Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This prospective, multicenter, non-interventional study will enroll participants from routine
clinical practice in Germany who are receiving tocilizumab for RA. The objective of the study
is systematic collection of data on use of tocilizumab in daily routine with special emphasis
on treatment decision by the prescriber, compliance with Summary of Product Characteristics
(SmPC), and documentation of relevant activity scores and adverse drug reactions (ADRs). The
maximum observation period will be 12 months per participant.